- Home
- APPS vs EYPT Comparison
APPS vs EYPT Comparison
Compare APPS & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APPS
- EYPT
- Stock Information
- Founded
- APPS N/A
- EYPT 1987
- Country
- APPS United States
- EYPT United States
- Employees
- APPS N/A
- EYPT N/A
- Industry
- APPS Multi-Sector Companies
- EYPT Biotechnology: Laboratory Analytical Instruments
- Sector
- APPS Miscellaneous
- EYPT Industrials
- Exchange
- APPS Nasdaq
- EYPT Nasdaq
- Market Cap
- APPS 562.7M
- EYPT 579.4M
- IPO Year
- APPS N/A
- EYPT 2005
- Fundamental
- Price
- APPS $5.46
- EYPT $10.48
- Analyst Decision
- APPS Hold
- EYPT Strong Buy
- Analyst Count
- APPS 3
- EYPT 8
- Target Price
- APPS $3.33
- EYPT $24.75
- AVG Volume (30 Days)
- APPS 4.5M
- EYPT 741.5K
- Earning Date
- APPS 08-05-2025
- EYPT 08-06-2025
- Dividend Yield
- APPS N/A
- EYPT N/A
- EPS Growth
- APPS N/A
- EYPT N/A
- EPS
- APPS N/A
- EYPT N/A
- Revenue
- APPS $490,506,000.00
- EYPT $56,042,000.00
- Revenue This Year
- APPS $8.47
- EYPT N/A
- Revenue Next Year
- APPS $8.74
- EYPT N/A
- P/E Ratio
- APPS N/A
- EYPT N/A
- Revenue Growth
- APPS N/A
- EYPT 12.04
- 52 Week Low
- APPS $1.18
- EYPT $3.91
- 52 Week High
- APPS $7.77
- EYPT $13.99
- Technical
- Relative Strength Index (RSI)
- APPS 51.89
- EYPT 59.34
- Support Level
- APPS $4.88
- EYPT $10.26
- Resistance Level
- APPS $5.68
- EYPT $11.00
- Average True Range (ATR)
- APPS 0.35
- EYPT 0.64
- MACD
- APPS -0.04
- EYPT -0.07
- Stochastic Oscillator
- APPS 53.21
- EYPT 42.11
About APPS Digital Turbine Inc.
Digital Turbine Inc is an independent mobile growth platform. It offers end-to-end products and solutions to all participants in the mobile application ecosystem, enabling brand discovery and advertising, user acquisition and engagement, and operational efficiency for advertisers. Its operating segments are On Device Solutions and App Growth Platform.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.